JW completes phase 3 study for biological response modifier

Published: 2011-03-21 06:57:00
Updated: 2011-03-21 06:57:00
JW Pharmaceutical said Thursday it has completed its local Phase III study for Actemra (tocilizumab), an investigational biological therapy for rheumatoid arthritis.

According to the company, the local Phase III study of 100 subjects was conducted in several general hospitals from October 2009...

Fees

- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.



Most Read News


TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.